PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

PharmaShots

FEBRUARY 24, 2023

Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive

FDA 40

FDA Vaccines 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 10, 2023

LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema Date: Feb 10, 2023 | Tags: LEO Pharma, Delgocitinib, Chronic Hand Eczema, Clinical Trial, P-III, DELTA 2 Trial GSK’s Jemperli (dostarlimab-gxly) Receives the US FDA’s Regular Approval for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 3, 2023

4D Molecular Therapeutics Receives the US FDA’s IND Clearance of 4D-150 for the Treatment of Diabetic Macular Edema Date: Feb 03, 2023 | Tags: 4D Molecular Therapeutics, 4D-150, Diabetic Macular Edema, Regulatory, US, FDA, IND AstraZeneca and Amgen Receive the US FDA’s Approval of Tezspire (tezepelumab) for the Treatment of Severe Asthma (..)

FDA 40

FDA Labelling 40

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. . It was backed by NICE for NHS use in July 2018. The post NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta appeared first on.

Hospitals 111

Hospitals Documentation 111

pharmaphorum

NOVEMBER 16, 2021

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. The post Drug-resistant epilepsy drug Ontozry backed by NICE appeared first on.

Documentation 94

Documentation 94

pharmaphorum

JANUARY 9, 2023

” Zolgensma is one of the most expensive therapies available, with a price tag of around $2.1 ” NHS England said the temporary change in eligibility – which ties in with NICE guidance – has been implemented as there are two other disease-modifying drugs available on the NHS for the treatment of SMA.

119

119

pharmaphorum

JUNE 2, 2021

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. “NICE’s initial ‘no’ to approving risdiplam for NHS funding is not unexpected,” said SMA UK this morning.

Documentation 52

Documentation Communication 52

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5

FDA 105

FDA 105

IDStewardship

MAY 13, 2023

It has claimed the tag line “The Antimicrobial Stewardship Meeting.” The Location and Timing on the Calendar As a Floridian it is fantastic to be able to drive a few hours to get here, but many attendees coming from afar have commented on how it is nice to get some sun on their face and spend time in the warm weather.

Communication 130

Communication 130

pharmaphorum

NOVEMBER 24, 2022

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

Labelling 52

Labelling Hospitals 52

pharmaphorum

FEBRUARY 22, 2021

News of the pause came as UK cost-effectiveness watchdog NICE rejected Zynteglo for regular NHS use in first draft guidance, despite a confidential discount to its price tag of around €1.57 million in Europe. The post Zynteglo halt re-ignites viral vector safety concerns; analysts appeared first on.

Immunization 52

Immunization 52

pharmaphorum

FEBRUARY 16, 2021

It’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its beta thalassaemia gene therapy Zynteglo for regular NHS use in first draft guidance. NICE said that data came from a small sample of patients and is using its standard discount rate of 3.5% million in Europe.

72

72

pharmaphorum

NOVEMBER 16, 2022

The UK’s NICE, the cost-effectiveness body for the country, immediately ruled that such pricing was beyond what the healthcare system could afford. However, with a price tag of €1.58 However, a recently released report from the organisation could blow the price tag of Zolgensma out of the water. At more than $2.1

130

130

European Pharmaceutical Review

MAY 11, 2023

3 The one-time gene therapy received final draft guidance from the National Institute for Health and Care Excellence (NICE) on 16 March 2023. 1 This is assuming a $1M price tag for all gene therapies. While Zolgensma is also being investigated in the form of an injection, the MOA currently approved by the FDA is a single infusion.

FDA 70

FDA 70

The Social Pharmacist

AUGUST 10, 2022

Encourage them to post it on their respective social media pages and tag you at the end. This strategy works great if your customers and followers already love tagging you in their Instagram Stories or regularly use your branded hashtag in their posts. For example, ask them for their best Christmas joke, funniest Christmas story, etc.

Packaging 52

Packaging 52

The Social Pharmacist

AUGUST 10, 2022

Encourage them to post it on their respective social media pages and tag you at the end. This strategy works great if your customers and followers already love tagging you in their Instagram Stories or regularly use your branded hashtag in their posts. For example, ask them for their best Christmas joke, funniest Christmas story, etc.

Packaging 40

Packaging 40

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years. Novo Nordisk is another company leading the charge in this field.

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. NICE has only allowed healthcare providers to prescribe continuous treatment of the drug for two years. Novo Nordisk is another company leading the charge in this field.

Insurance 98

Insurance Labelling Communication FDA 98

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40